Scancell (LON:SCLP) Stock Price Up 5.1% - What's Next?

Key Points

• Scancell Holdings plc's stock price increased by 5.1%, trading as high as GBX 10.50 ($0.14) during mid-day trading, significantly above its previous close of GBX 9.75 ($0.13).
• Insider Martin Diggle purchased 44,944 shares at an average price of GBX 9 ($0.12), indicating confidence in the company's future.
• Scancell is a clinical stage immunotherapy biotech firm focused on developing treatments for hard-to-treat cancers, with a pipeline of innovative vaccine and antibody therapies.

Scancell Holdings plc (LON:SCLP - )'s share price rose 5.1% during mid-day trading on Friday . The company traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.25 ($0.14). Approximately 9,863,690 shares changed hands during mid-day trading, an increase of 953% from the average daily volume of 936,871 shares. The stock had previously closed at GBX 9.75 ($0.13).

Scancell Stock Performance

The business's fifty day moving average price is GBX 9.90 and its 200-day moving average price is GBX 9.43. The stock has a market capitalization of £112.27 million, a PE ratio of -16.62 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01.

Insider Transactions at Scancell

In other news, insider Martin Diggle purchased 44,944 shares of the business's stock in a transaction on Tuesday, May 20th. The stock was purchased at an average cost of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,343.41). 4.96% of the stock is owned by corporate insiders.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.